{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:17:59Z","timestamp":1794475079357,"version":"4.9.1"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"\n Importance<\/jats:title>\n Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn &amp;amp; Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the change of Movement Disorder Society Unified Parkinson\u2019s Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, \u22125.10 to 7.03,\n P<\/jats:italic>\n \u2009=\u2009.75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%];\n P<\/jats:italic>\n \u2009=\u2009.003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n FMT was safe but did not offer clinically meaningful improvements. Further studies\u2014for example, through modified FMT approaches or bowel cleansing\u2014are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04854291<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.2305","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:52:27Z","timestamp":1722253947000},"page":"925","source":"Crossref","is-referenced-by-count":143,"title":["Fecal Microbiota Transplantation for Treatment of Parkinson Disease"],"prefix":"10.1001","volume":"81","author":[{"given":"Filip","family":"Scheperjans","sequence":"first","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"},{"name":"Clinicum, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"Levo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Bosch","sequence":"additional","affiliation":[{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"L\u00e4\u00e4peri","sequence":"additional","affiliation":[{"name":"L\u00e4\u00e4peri Statistical Consulting, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A. B.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli-Pekka","family":"Smolander","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velma T. E.","family":"Aho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Vetkas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Toivio","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veera","family":"Kainulainen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, Helsinki, Finland"},{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana D.","family":"Fedorova","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine - Nuclear Medicine and Positron Emission Tomography, Aarhus University, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Lahtinen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, P\u00e4ij\u00e4t-H\u00e4me Central Hospital, Lahti, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tampere University Hospital and University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences, University of Turku and Neurocenter, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"Satokari","sequence":"additional","affiliation":[{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[{"name":"Clinicum, University of Helsinki, Helsinki, Finland"},{"name":"Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"noi240044r1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","article-title":"The microbiome-gut-brain axis in Parkinson disease\u2014from basic research to the clinic.","volume":"18","author":"Tan","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"noi240044r2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41531-021-00191-w","article-title":"Early constipation predicts faster dementia onset in Parkinson\u2019s disease.","volume":"7","author":"Camacho","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"noi240044r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101834","article-title":"Premotor, nonmotor and motor symptoms of Parkinson\u2019s disease: a new clinical state of the art.","volume":"84","author":"Leite Silva","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"3","key":"noi240044r4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","article-title":"Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype.","volume":"30","author":"Scheperjans","year":"2015","journal-title":"Mov Disord"},{"key":"noi240044r5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","article-title":"Gut microbiota in Parkinson\u2019s disease: Temporal stability and relations to disease progression.","volume":"44","author":"Aho","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"noi240044r6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JPD-202297","article-title":"Does gut microbiota influence the course of Parkinson\u2019s disease? a 3-year prospective exploratory study in de novo patients.","volume":"11","author":"Cilia","year":"2021","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"noi240044r7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-022-00328-5","article-title":"Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson\u2019s disease.","volume":"8","author":"Nishiwaki","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"noi240044r8","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1111\/ene.15671","article-title":"Gut microbiota dysbiosis in Parkinson disease: a systematic review and pooled analysis.","volume":"30","author":"Kleine Bardenhorst","year":"2023","journal-title":"Eur J Neurol"},{"key":"noi240044r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2021.11.017","article-title":"Gut microbiome in Parkinson\u2019s disease: new insights from meta-analysis.","volume":"94","author":"Toh","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"noi240044r10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41531-022-00395-8","article-title":"Fecal microbiome alterations in treatment-naive de novo Parkinson\u2019s disease.","volume":"8","author":"Boertien","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"noi240044r11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24021001","article-title":"The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review.","volume":"24","author":"Matheson","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"noi240044r12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-021-00427-6","article-title":"Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease.","volume":"16","author":"Aho","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"8","key":"noi240044r13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/mds.29128","article-title":"Bacterial butyrate in Parkinson\u2019s disease is linked to epigenetic changes and depressive symptoms.","volume":"37","author":"Xie","year":"2022","journal-title":"Mov Disord"},{"issue":"8","key":"noi240044r14","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s10571-021-01128-w","article-title":"Probiotics and the treatment of Parkinson\u2019s disease: an update.","volume":"42","author":"Mirzaei","year":"2022","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"noi240044r15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/microorganisms11122901","article-title":"Development of a protocol for anaerobic preparation and banking of fecal microbiota transplantation material: evaluation of bacterial richness in the cultivated fraction.","volume":"11","author":"Bosch","year":"2023","journal-title":"Microorganisms"},{"issue":"4","key":"noi240044r16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice.","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"issue":"3 Pt 2","key":"noi240044r17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.gie.2008.05.057","article-title":"The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research.","volume":"69","author":"Lai","year":"2009","journal-title":"Gastrointest Endosc"},{"issue":"15","key":"noi240044r18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society\u2013sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"4","key":"noi240044r19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"noi240044r20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"noi240044r21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00421-017-3739-1","article-title":"Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners.","volume":"117","author":"Karhu","year":"2017","journal-title":"Eur J Appl Physiol"},{"issue":"20","key":"noi240044r22","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.3639","article-title":"Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?","volume":"28","author":"Liu","year":"2009","journal-title":"Stat Med"},{"issue":"5","key":"noi240044r23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.chom.2022.03.002","article-title":"Dynamics of the normal gut microbiota: a longitudinal one-year population study in Sweden.","volume":"30","author":"Olsson","year":"2022","journal-title":"Cell Host Microbe"},{"key":"noi240044r24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","article-title":"Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: gut microbiota, glial reaction and TLR4\/TNF-a signaling pathway.","volume":"70","author":"Sun","year":"2018","journal-title":"Brain Behav Immun"},{"issue":"1","key":"noi240044r25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3892\/etm.2021.10974","article-title":"Gut microbiota relieves inflammation in the substantia nigra of chronic Parkinson\u2019s disease by protecting the function of dopamine neurons.","volume":"23","author":"Zhang","year":"2022","journal-title":"Exp Ther Med"},{"issue":"1","key":"noi240044r26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40168-021-01107-9","article-title":"Fecal microbiota transplantation protects rotenone-induced Parkinson\u2019s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.","volume":"9","author":"Zhao","year":"2021","journal-title":"Microbiome"},{"key":"noi240044r27","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.14309\/00000434-200910003-00999","article-title":"Treatment of severe constipation improves Parkinson\u2019s disease (PD) symptoms.","volume":"104","author":"Borody","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"noi240044r28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016163","article-title":"Fecal microbiota transplantation to treat Parkinson\u2019s disease with constipation: a case report.","volume":"98","author":"Huang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"35","key":"noi240044r29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022035","article-title":"Fecal microbiota transplantation therapy for Parkinson\u2019s disease: a preliminary study.","volume":"99","author":"Xue","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"noi240044r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106791","article-title":"Fecal microbiota transplant as a potential treatment for Parkinson\u2019s disease\u2014a case series.","volume":"207","author":"Segal","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"noi240044r31","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-021-01589-0","article-title":"Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation.","volume":"20","author":"Kuai","year":"2021","journal-title":"Microb Cell Fact"},{"key":"noi240044r32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1104759","article-title":"Fecal microbiota transplantation in Parkinson\u2019s disease\u2014a randomized repeat-dose, placebo-controlled clinical pilot study.","volume":"14","author":"DuPont","year":"2023","journal-title":"Front Neurol"},{"key":"noi240044r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105410","article-title":"Fecal microbiota transplantation for Parkinson\u2019s disease using levodopa\u2014carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube.","volume":"111","author":"Chernova","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"noi240044r34","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2284247","article-title":"Efficacy of fecal microbiota transplantation in patients with Parkinson\u2019s disease: clinical trial results from a randomized, placebo-controlled design.","volume":"15","author":"Cheng","year":"2023","journal-title":"Gut Microbes"},{"key":"noi240044r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102563","article-title":"Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial.","volume":"71","author":"Bruggeman","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"7","key":"noi240044r36","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s10620-021-07141-9","article-title":"Heterogeneity of randomized controlled trials of fecal microbiota transplantation in recurrent clostridioides difficile infection.","volume":"67","author":"Feuerstadt","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"8","key":"noi240044r37","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1039\/D2FO03825K","article-title":"Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson\u2019s disease.","volume":"14","author":"Chu","year":"2023","journal-title":"Food Funct"},{"issue":"5","key":"noi240044r38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society\u2013sponsored Unified Parkinson\u2019s Disease Rating Scale.","volume":"32","author":"Horv\u00e1th","year":"2017","journal-title":"Mov Disord"},{"issue":"12","key":"noi240044r39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the motor examination part of MDS-UPDRS.","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"noi240044r40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.parkreldis.2011.03.014","article-title":"The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.","volume":"17","author":"Anderson","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"noi240044r41","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","article-title":"Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.","volume":"67","author":"Halkj\u00e6r","year":"2018","journal-title":"Gut"},{"key":"noi240044r42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.574529","article-title":"Effect of levodopa initiation on the gut microbiota in Parkinson\u2019s disease.","volume":"12","author":"Palacios","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"noi240044r43","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1038\/s41598-019-40182-9","article-title":"Effects of bowel preparation on the human gut microbiome and metabolome.","volume":"9","author":"Nagata","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"noi240044r44","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1136\/gutjnl-2014-307240","article-title":"Effects of bowel cleansing on the intestinal microbiota.","volume":"64","author":"Jalanka","year":"2015","journal-title":"Gut"},{"issue":"2","key":"noi240044r45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cells9020376","article-title":"Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson\u2019s disease.","volume":"9","author":"Hegelmaier","year":"2020","journal-title":"Cells"},{"key":"noi240044r46","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.729961","article-title":"intestinal decontamination therapy for dyskinesia and motor fluctuations in Parkinson\u2019s disease.","volume":"12","author":"Baizabal-Carvallo","year":"2021","journal-title":"Front Neurol"},{"issue":"2","key":"noi240044r47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3233\/JPD-161050","article-title":"Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson\u2019s disease: a colon transit and volume study.","volume":"7","author":"Knudsen","year":"2017","journal-title":"J Parkinsons Dis"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2821254\/jamaneurology_scheperjans_2024_oi_240044_1725483557.37006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T11:07:06Z","timestamp":1725880026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2821254"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.2305","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}